Chest Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Noninvasive Oxygenation Strategies in Adult Patients With Acute Hypoxemic Respiratory Failure 2023
• Observation, Aspiration, or Tube Thoracostomy for Primary Spontaneous Pneumothorax 2023
• Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia 2023
• MALIGNANT TRANSFORMATION OF A SOLITARY TRACHEAL PAPILLOMA IN THE ABSENCE OF HUMAN PAPILLOMAVIRUS INFECTION IN A PATIENT WITH 48, XYYY SYNDROME: CASE REPORT 2022
• Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease 2022
• Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease 2022
• Effects of Traffic-Related Air Pollution on Exercise Endurance, Dyspnea, and Cardiorespiratory Responses in Health and COPD 2022
• STREPTOCOCCAL TOXIC SHOCK SYNDROME SECONDARY TO UNCOMMON GROUP G VARIANT REQUIRING IMMUNOGLOBULIN THERAPY 2021
• Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2021
• ENDOBRONCHIAL ULTRASOUND STAGING OF OPERABLE NSCLC: TRIPLE NEGATIVE LYMPH NODES MAY NOT REQUIRE ROUTINE BIOPSY 2019
• ENHANCING PULMONARY REHABILITATION ENROLMENT STUDY (PRESS III) 2018
• POWER: Prospective Cohort Study for the Real-Life Effectiveness Evaluation of Glycopyrronium With Indacaterol Combination in the Management of COPD in Canada 2016
• Pleural Solitary Fibrous Stromal Tumor: Beware of the Elevated Hemidiaphragm 2016
• Community-Acquired Pneumonia in Older and Younger Adults With Diabetes Mellitus 2015
• GOLD Stage and Treatment in COPD: A 500 Patient Point Prevalence Study 2015
• Low Prevalence of High Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study 2015
• Physiologic Characterization of the Chronic Bronchitis Phenotype in GOLD Grade IB COPD 2015
• Evaluation of a Novel Method of Teaching Endobronchial Ultrasound: Interventional Pulmonologist Versus Respiratory Therapist Proctored Simulation Training 2013
• Intracavitary Pulmonary Aspergilloma Removal Using Combined Virtual, Ultrathin, and Rigid Bronchoscopy - A Case Series 2013
• Oscillatory Positive Expiratory Pressure (oPEP) Treatment in Chronic Obstructive Pulmonary Disease 2013
• Weaning Dobutamine in a Patient With Severe Cardiogenic Shock Using Hemodynamic Transesophageal Echocardiography 2013
• A SINGLE DOSE OF MEDI-528, A MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-9, IS WELL TOLERATED IN MILD AND MODERATE ASTHMATICS IN THE PHASE II TRIAL MI-CP-138 2007
• A RANDOMIZED TRIAL OF STRATEGIES FOR ASSESSING ELIGIBILITY FOR LONG-TERM DOMICILIARY OXYGEN THERAPY 2005
• Do restrictive reimbursement processes inhibit physicians from adopting and implementing guidelines into their practice: The Canadian asthma experience 2005
• FACTORS AFFECTING SUCCESSFUL TRANSITION FROM HIGH FREQUENCY OSCILLATION TO CONVENTIONAL MECHANICAL VENTILATION IN ADULT PATIENTS 2005
• LUNG DEPOSITION OF QVAR (HFA134A-BDP) IN NEWBORN INFANTS WITH BRONCHOPULMONARY DYSPLASIA (BPD) 2005
• RESISTANCE PHENOTYPES OF STREPTOCOCCUS PNEUMONIAE AND CLINICAL OUTCOME OF RESPIRATORY TRACT INFECTIONS TREATED WITH GEMIFLOXACIN 2005
• RISK PROFILES AND PROPHYLAXIS HISTORY OF PATIENTS DEVELOPING VENOUS THROMBOEMBOLISM IN THE OUTPATIENT SETTING: THE WORCESTER VENOUS THROMBOEMBOLISM STUDY 2005
• THE CHANGING LANDSCAPE OF VENOUS THROMBOEMBOLISM: THE WORCESTER VENOUS THROMBOEMBOLISM STUDY 2005
• The 2005 asthma action study in Canada 2005
• An overview of the efficacy of gemifloxacin for the treatment of community-acquired pneumonia (CAP) 2004
• Early vs delayed initiation of fondaparinux prophylaxis to prevent postoperative pulmonary embolism: A clinical endpoint study 2004
• Improved Aerosolization of Suspensions Using Electronic Micropump Technology Compared to Conventional Pneumatic Nebulization 2004
• Safety and Efficacy of Gemifloxacin Compared to High Dose Amoxicillin/Clavulanate for the Treatment of Community-Acquired Pneumonia (CAP) of Suspected Pneumococcal Origin 2004
• Safety and Tolerability of Gemifloxacin: A Review of Clinical Trial Data 2004
• The Efficacy of 5-Day Gemifloxacin Once Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis (AECB) 2004
• Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction 2004
• Continuously nebulized albuterol versus intermittently nebulized albuterol treatment in patients hospitalized with chronic obstructive pulmonary disease exacerbation 2003
• Airway Hyperresponsiveness 2003
• Adenovirus-Mediated Gene Transfer of the Proteoglycan Biglycan Induces Fibroblastic Responses in the Lung 1997
• In Vivo Adenovirus-Mediated Expression of Human Pre-Elafin, a Potent Neutrophil Elastase Inhibitor 1997
• From the Bench to the Bedside: The Future of Sepsis Research 1997
• The Clinical Efficacy of Combination Nebulized Anticholinergic and Adrenergic Bronchodilators vs Nebulized Adrenergic Bronchodilator Alone in Acute Asthma 1997
• ANTITHROMBOTIC THERAPY IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY 1995
• Aspirin and Other Platelet-Active Drugs 1995
• Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism 1995
• NEW ANTITHROMBOTICS 1995
• Use of Antithrombotic Agents During Pregnancy 1995
• MORTALITY AMONG WORKERS WITH SILICOSIS IN ONTARIO 1987
• Lung Cancer in a Steel Foundry 1986
• TREATMENT OF OBSTRUCTIVE SLEEP-APNEA BY DIFFERENTIAL SUPRAHYOID MUSCLE REPOSITIONING 1985
• A PROSPECTIVE-STUDY OF VENTILATION-PERFUSION LUNG-SCANNING AND PULMONARY ANGIOGRAPHY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY-EMBOLISM 1982
• LUNG EPITHELIAL PERMEABILITY IN NORMAL SUBJECTS, ASTHMATICS AND SMOKERS 1982
• Lung Ultrasound in the ED: Will Death Do Us Part?.  166:418-419. 2024
• BAL Fluid Cellular Analysis and Radiologic Patterns in Patients With Fibrotic Interstitial Lung Disease..  S0012-3692(24)04930-4. 2024
• Use of Intravenous Albumin.  166:321-338. 2024
• Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis.  165:1435-1443. 2024
• CT Airway Mucus in Older People Without Chronic Respiratory Illness.  166:429-432. 2024
• The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung Disease.  166:517-527. 2024
• Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.  164:1466-1475. 2023
• EFFECTIVENESS OF BENRALIZUMAB AFTER 12 MONTHS OF TREATMENT IN CANADIANS WITH SEVERE ASTHMA.  164:a4898-a4900. 2023
• Fluid Therapy in Sepsis.  164:812-813. 2023
• Epinephrine in Out-of-Hospital Cardiac Arrest.  164:381-393. 2023
• Perioperative Management of Vitamin K Antagonists and Direct Oral Anticoagulants.  163:1245-1257. 2023
• Outpatient Mental Health Follow-up and Recurrent Self-harm and Suicide Among Patients Admitted to the ICU for Self-harm.  163:815-825. 2023
• Critical Care Transesophageal Echocardiography for the Resuscitation of Shock.  163:268-269. 2023
• Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease.  163:345-357. 2023
• Corticosteroids in Community-Acquired Pneumonia.  163:e47-e48. 2023
• COVID-19.  162:1297-1305. 2022
• Executive Summary.  162:1127-1139. 2022
• Perioperative Management of Antithrombotic Therapy.  162:e207-e243. 2022
• Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose.  162:520-533. 2022
• Implications of the COVID-19 Pandemic for the Well-Being of the ICU Workforce Considerations for the ICU Interprofessional Team.  162:285-287. 2022
• A 68-Year-Old Woman With Refractory Cough and Insidious Tracheal Thickening.  161:e287-e291. 2022
• Complications of Critical COVID-19.  161:989-998. 2022
• Detection and Early Referral of Patients With Interstitial Lung Abnormalities.  161:470-482. 2022
• VTE Prophylaxis in Critically Ill Adults.  161:418-428. 2022
• Persistent Exertional Intolerance After COVID-19.  161:54-63. 2022
• The Usefulness of the Rapid Shallow Breathing Index in Predicting Successful Extubation.  161:97-111. 2022
• Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis.  160:2158-2162. 2021
• Caution When Comparing the Impact of Corticosteroids in COVID-19.  160:e243-e244. 2021
• Risk Perception Among a Lung Cancer Screening Population.  160:718-730. 2021
• The Burden of Mental Illness Among Survivors of Critical Care—Risk Factors and Impact on Quality of Life.  160:157-164. 2021
• Endobronchial Ultrasound Staging of Operable Non-small Cell Lung Cancer.  159:2470-2476. 2021
• Response.  159:2115-2115. 2021
• Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation.  159:e181-e184. 2021
• Dosing Fluids in Early Septic Shock.  159:1493-1502. 2021
• Response.  159:1301-1302. 2021
• Lung-Protective Ventilation and Associated Outcomes and Costs Among Patients Receiving Invasive Mechanical Ventilation in the ED.  159:606-618. 2021
• A Tool to Assess Participation in People With COPD.  159:138-146. 2021
• POINT: Should Corticosteroids Be Routine Treatment in Early ARDS? Yes.  159:25-29. 2021
• Rebuttal From Drs Meduri and Rochwerg.  159:35-37. 2021
• Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge.  158:2270-2274. 2020
• High-Flow Nasal Cannula in the Immediate Postoperative Period.  158:1934-1946. 2020
• Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma.  158:1350-1360. 2020
• Key Highlights of the Canadian Thoracic Society’s Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic.  158:869-872. 2020
• Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic.  158:1069-1078. 2020
• Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis.  158:479-490. 2020
• Luminal Eosinophil Cell Death as a Biomarker for Loss of Asthma Control?.  157:1680-1681. 2020
• Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease.  157:1207-1220. 2020
• The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough.  157:111-118. 2020
• Nonidentical Twins With Asthma.  156:e111-e116. 2019
• Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease.  156:887-895. 2019
• Response.  156:808-809. 2019
• Determinants of Depressive Symptoms at 1 Year Following ICU Discharge in Survivors of ≥ 7 Days of Mechanical Ventilation.  156:466-476. 2019
• CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma.  155:1178-1189. 2019
• The Aging Lung.  155:391-400. 2019
• Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD.  155:69-78. 2019
• Spread the Word About CHEST in 2019.  155:1-4. 2019
• Antimicrobial Resistance and Respiratory Infections.  154:1202-1212. 2018
• Expiratory Flow Limitation During Mechanical Ventilation.  154:948-962. 2018
• Sepsis-3 Septic Shock Criteria and Associated Mortality Among Infected Hospitalized Patients Assessed by a Rapid Response Team.  154:309-316. 2018
• Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay.  153:1396-1404. 2018
• The Impact of Listening to Music During a High-Intensity Exercise Endurance Test in People With COPD.  153:1134-1141. 2018
• Giants in Chest Medicine.  153:776-777. 2018
• IV Immunoglobulin for Autoimmune Heparin-Induced Thrombocytopenia.  152:453-455. 2017
• Hematopoietic Processes in Eosinophilic Asthma.  152:410-416. 2017
• Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding.  152:81-91. 2017
• Epithelial-Derived Cytokines in Asthma.  151:1338-1344. 2017
• The Potential Role of Aspiration in the Asthmatic Airway.  151:1272-1278. 2017
• An Update on Lymphocyte Subtypes in Asthma and Airway Disease.  151:1122-1130. 2017
• Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants.  151:127-138. 2017
• POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? Yes.  151:14-17. 2017
• Rebuttal From Dr O’Byrne.  151:20-21. 2017
• Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study.  150:1015-1022. 2016
• Measuring Eosinophils to Make Treatment Decisions in Asthma.  150:485-487. 2016
• Platelet Activation Testing for Heparin-Induced Thrombocytopenia Antibodies.  150:478-480. 2016
• Objective Cough Frequency, Airway Inflammation, and Disease Control in Asthma.  149:1460-1466. 2016
• Surfactant Protein-D and Asthma.  149:1121-1122. 2016
• Interpretability of Change Scores in Measures of Balance in People With COPD.  149:696-703. 2016
• Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.  149:315-352. 2016
• Platelet Transfusion Practices in the ICU: Data From a Large Transfusion Registry.  150:516-523. 2016
• Correction to Dosage in: Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis: 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  148:1529-1529. 2015
• Table in: Dosing Frequency of Unfractionated Heparin Thromboprophylaxis: A Meta-analysis (vol 140, pg 374, 2011).  148:1363-1363. 2015
• Timing the First Postoperative Dose of Anticoagulants.  148:587-595. 2015
• Distractive Auditory Stimuli in the Form of Music in Individuals With COPD.  148:417-429. 2015
• The Role for Optical Density in Heparin-Induced Thrombocytopenia.  148:55-61. 2015
• Pain and Its Clinical Associations in Individuals With COPD.  147:1246-1258. 2015
• Physiologic Characterization of the Chronic Bronchitis Phenotype in GOLD Grade IB COPD.  147:1235-1245. 2015
• Hospitalized Exacerbations of COPD.  147:999-1007. 2015
• Family-Based Psychosocial Support and Education as Part of Pulmonary Rehabilitation in COPD.  147:662-672. 2015
• Is Quadriceps Endurance Reduced in COPD?.  147:673-684. 2015
• Self-Management Following an Acute Exacerbation of COPD.  147:646-661. 2015
• The Effect of Omega-3 Fatty Acids on Bronchial Hyperresponsiveness, Sputum Eosinophilia, and Mast Cell Mediators in Asthma.  147:397-405. 2015
• Development of a novel, multilayered presentation format for clinical practice guidelines.  147:754-763. 2015
• Spread the Word About CHEST in 2015.  147:1-3. 2015
• New Approaches to TB Vaccination.  146:804-812. 2014
• Risk of Mycobacterial Infections Associated With Rheumatoid Arthritis in Ontario, Canada.  146:563-572. 2014
• Do Field Walking Tests Produce Similar Cardiopulmonary Demands to an Incremental Treadmill Test in Obese Individuals With Treated OSA?.  146:81-87. 2014
• A Man in His 40s With Fever and Hypotension.  145:e17-e19. 2014
• Measurement Properties of the Incremental Shuttle Walk Test.  145:1357-1369. 2014
• Non-Vitamin K Antagonist Oral Anticoagulants.  145:1177-1178. 2014
• Response.  145:1174-1175. 2014
• Measurement of Activities of Daily Living in Patients With COPD.  145:253-271. 2014
• Trends in the Prevalence of Asthma.  145:219-225. 2014
• Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process.  146:727-734. 2014
• Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the antithrombotic therapy and the prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  146:735-761. 2014
• A Randomized Controlled Trial of Balance Training During Pulmonary Rehabilitation for Individuals With COPD.  144:1803-1810. 2013
• Airways Disease Presenting as Restrictive Impairment: Response.  144:1979-1980. 2013
• Perioperative Management of Antiplatelet Therapy in Patients With a Coronary Stent Who Need Noncardiac Surgery.  144:1848-1856. 2013
• Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma.  144:1222-1229. 2013
• Improving Clinical Interpretation of the Anti-Platelet Factor 4/Heparin Enzyme-Linked Immunosorbent Assay for the Diagnosis of Heparin-Induced Thrombocytopenia Through the Use of Receiver Operating Characteristic Analysis, Stratum-Specific Likelihood Ratios, and Bayes Theorem.  144:1269-1275. 2013
• Interruption of Warfarin Anticoagulation for Dental Surgery: Response.  144:1424-1426. 2013
• Systematic Review of Supervised Exercise Programs After Pulmonary Rehabilitation in Individuals With COPD.  144:1124-1133. 2013
• Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis.  144:1207-1215. 2013
• Variation in Diagnostic Testing in Intensive Care Units: A Comparison of Teaching and Nonteaching Hospitals in a Regional System.  144:582a-582b. 2013
• Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness.  144:848-858. 2013
• Creating Clinical Practice Guidelines.  144:365-367. 2013
• Detection of COPD Exacerbations and Compliance With Patient-Reported Daily Symptom Diaries Using a Smartphone-Based Information System.  144:507-514. 2013
• Arm Elevation and Coordinated Breathing Strategies in Patients With COPD.  144:128-135. 2013
• The Occurrence and Impact of Bacterial Organisms Complicating Critical Care Illness Associated With 2009 Influenza A(H1N1) Infection.  144:39-47. 2013
• American College of Chest Physicians Guidelines for Heparin-Induced Thrombocytopenia: Response.  143:1191-1191. 2013
• Protein Misfolding and Endoplasmic Reticulum Stress in Chronic Lung Disease.  143:1098-1105. 2013
• Are Asymptomatic DVTs Relevant? One Measure for All Response.  143:874-875. 2013
• Asthma Associated With Incontinentia Pigmenti and Fanconi Anemia.  143:856-858. 2013
• The Poorly Explored Impact of Uncontrolled Asthma.  143:511-523. 2013
• Are Asymptomatic DVTs Relevant?: Response.  143:874-875. 2013
• Creating clinical practice guidelines we can trust, use, and share: a new era is imminent.  144:381-389. 2013
• Experiences with a novel policy for managing conflicts of interest of guideline developers: a descriptive qualitative study.  144:398-404. 2013
• Low anonymous voting compliance with the novel policy for managing conflicts of interest implemented in the 9th version of the American College of Chest Physicians antithrombotic guidelines.  144:1111-1116. 2013
• The Influence of Cigarette Smoking on Viral Infections.  143:196-206. 2013
• Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (vol 141, pg 7S, 2012).  142:1698-1698. 2012
• The Pros and Cons of Propensity Scores.  142:1380-1382. 2012
• Heparin-Induced Thrombocytopenia in the ICU.  142:815-816. 2012
• Role of Cystic Fibrosis Transmembrane Conductance Regulator in Patients With Chronic Sinopulmonary Disease.  142:996-1004. 2012
• Safety and Feasibility of Femoral Catheters During Physical Rehabilitation in the ICU.  142:365A-365A. 2012
• Pulmonary Rehabilitation.  142:738-749. 2012
• Angiogenesis in Pulmonary Fibrosis.  142:200-207. 2012
• Impairments in Systems Underlying Control of Balance in COPD.  141:1496-1503. 2012
• Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (vol 141, pg 7S, 2012).  141:1129-1129. 2012
• Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (vol 141, pg e326S, 2012).  141:1129-1129. 2012
• Mine Is Bigger Than Yours.  141:595-598. 2012
• Antiplatelet Drugs.  141:e89S-e119S. 2012
• Antithrombotic Therapy for Atrial Fibrillation.  141:e531S-e575S. 2012
• Antithrombotic Therapy in Neonates and Children.  141:e737S-e801S. 2012
• Defining the Relationship Between Average Daily Energy Expenditure and Field-Based Walking Tests and Aerobic Reserve in COPD.  141:406-412. 2012
• Diagnosis of DVT.  141:e351S-e418S. 2012
• Evidence-Based Management of Anticoagulant Therapy.  141:e152S-e184S. 2012
• New Antithrombotic Drugs.  141:e120S-e151S. 2012
• Oral Anticoagulant Therapy.  141:e44S-e88S. 2012
• Parenteral Anticoagulants.  141:e24S-e43S. 2012
• Perioperative Management of Antithrombotic Therapy.  141:e326S-e350S. 2012
• Prevention of VTE in Orthopedic Surgery Patients.  141:e278S-e325S. 2012
• Severe Bronchorrhea in a Patient with Bronchioloalveolar Carcinoma.  141:513-514. 2012
• The Effect of Pulmonary Rehabilitation on Critical Walk Speed in Patients With COPD.  141:413-419. 2012
• Treatment and Prevention of Heparin-Induced Thrombocytopenia.  141:e495S-e530S. 2012
• VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy.  141:e691S-e736S. 2012
• American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:7S-47S. 2012
• American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:e419S-94S. 2012
• Antithrombotic and thrombolytic therapy for ischemic stroke.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  141:e601S-e636S. 2012
• Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  141:e601S-e636S. 2012
• Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:e419S-94S. 2012
• Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:e419S-e496S. 2012
• Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  141:e669S-e690S. 2012
• Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  141:e185S-e194S. 2012
• Clarification of Once-Daily Low-Molecular-Weight Heparin Dosing in Pulmonary Embolism: Response.  142:1075-1076. 2012
• Do CIs Give You Confidence?.  141:17-19. 2012
• Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:7S-7S. 2012
• How Should We Measure Arm Exercise Capacity in Patients With COPD?.  141:111-120. 2012
• Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:48S-52S. 2012
• Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  141:53S-70S. 2012
• Panel List.  141:3S-3S. 2012
• Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  141:e1S-e23S. 2012
• Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials.  141:308-320. 2012
• Preventing VTE in Outpatients With Cancer: Response.  142:266-267. 2012
• Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:e195S-e226S. 2012
• Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.  141:e637S-e668S. 2012
• Serum Procalcitonin and Infective Exacerbations of Asthma.  140:1389-1390. 2011
• A Prospective Quality Assurance Study of Proper Utilization of Metered-Dose Inhalers in the Medical Inpatient Population.  140:1025a. 2011
• Evidence Incorporating Patients' Values: Response.  140:832-833. 2011
• Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE.  140:706-714. 2011
• Properties of Self-Paced Walking in Chronic Respiratory Disease.  140:737-743. 2011
• Dosing Frequency of Unfractionated Heparin Thromboprophylaxis.  140:374-381. 2011
• Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE.  140:366-373. 2011
• Correction for Multiple Testing.  140:16-18. 2011
• Early Postoperative Pulmonary Vascular Compliance Predicts Outcome After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension.  140:34-41. 2011
• Point: Is Measuring Sputum Eosinophils Useful in the Management of Severe Asthma? Yes.  139:1270-1273. 2011
• Rebuttal From Drs Hargreave and Nair.  139:1275-1277. 2011
• Assessing the Performance of the HAS-BLED Score: Response.  139:1248-1248. 2011
• Simulator Training for Recognition of Murmurs.  139:1257-1258. 2011
• The HAS-BLED Score and Renal Failure: Response.  139:1249-1250. 2011
• Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) (vol 133, pg 340S, 2008).  139:1261-1261. 2011
• Nontubercular Mycobacterial Pulmonary Infection in Severe Asthma.  139:721-721. 2011
• Alternative Therapy.  139:475-476. 2011
• Comparison of the Effect of Low-Dose Ciclesonide and Fixed-Dose Fluticasone Propionate and Salmeterol Combination on Long-term Asthma Control.  139:311-318. 2011
• The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness.  139:271-278. 2011
• Effects of water-pipe smoking on lung function: a systematic review and meta-analysis.  139:764-774. 2011
• Factors at Admission Associated With Bleeding Risk in Medical Patients.  139:69-79. 2011
• More Rigor Needed in Systematic Reviews on “Waterpipe”(Hookah, Narghile, Shisha) Smoking: Response.  139:1251-1252. 2011
• Resistance Arm Training in Patients With COPD.  139:151-158. 2011
• A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation.  138:1093-1100. 2010
• Benefit of Roflumilast Therapy Added to Salmeterol in Patients With Varying Chronic Obstructive Pulmonary Disease Severity.  138:467A-467A. 2010
• CHA 2 DS 2 -VASc Risk Scheme: Response.  138:1020-1021. 2010
• Efficacy of Roflumilast in Chronic Obstructive Pulmonary Disease Patients With or Without Inhaled Corticosteroid Pretreatment.  138:464A-464A. 2010
• Safety of Uninterrupted Anticoagulation in Patients Requiring Elective Coronary Angiography With or Without Percutaneous Coronary Intervention.  138:840-847. 2010
• The 4T and Chong Scores Correlate With Outcomes for Heparin-Induced Thrombocytopenia.  138:188A-188A. 2010
• Conclusion.  138:44S-45S. 2010
• Introduction.  138:1S-3S. 2010
• Measuring Bronchitis in Airway Diseases: Clinical Implementation and Application.  138:38S-43S. 2010
• Obstructive Sleep Apnea Is a Risk Factor for Stroke and Atrial Fibrillation: Response.  138:239-240. 2010
• A Comparison of Obese and Nonobese People With Asthma.  137:1316-1323. 2010
• Recent Advances in the Pathophysiology of Asthma.  137:1417-1426. 2010
• Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach.  137:263-272. 2010
• Deep Vein Thrombosis Prophylaxis: Response.  136:1700-1701. 2009
• Factors That Predict Risk of Thrombosis in Relatives of Patients With Unprovoked Venous Thromboembolism.  136:1537-1545. 2009
• The Effects of Inhaled Budesonide on Lung Function in Smokers and Nonsmokers With Mild Persistent Asthma.  136:1514-1520. 2009
• Changes in Exhaled Nitric Oxide Related to Estrogen and Progesterone During the Menstrual Cycle.  136:1301-1307. 2009
• ADDITIONAL CLINICAL BENEFIT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATED WITH ROFLUMILAST AND SALMETEROL.  136:3s-f1-3s-f2. 2009
• Medical Questionnaires Are Copyrighted To Ensure That Validity Is Maintained.  136:951-952. 2009
• THE PROFILE OF CHRONIC OBSTRUCTIVE DISEASE IN THE PRIMARY CARE SETTING.  136:87S-87S. 2009
• Safety of Long-Acting β-Agonists.  136:604-607. 2009
• Antiinflammatory Effects of Long-Acting β 2 -Agonists in Patients With Asthma.  136:145-154. 2009
• Balancing the Risks and Benefits of Thromboprophylaxis in Patients Undergoing Podiatric Surgery.  135:888-890. 2009
• The American College of Chest Physicians Evidence-Based Educational Guidelines for Continuing Medical Education Interventions.  135:834-837. 2009
• Variations and Gaps in Management of Acute Asthma in Ontario Emergency Departments.  135:724-736. 2009
• American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ.  135:513-520. 2009
• D-dimer in patients with clinically suspected pulmonary embolism. 1993..  136. 2009
• The Need for Expertise and the Scientific Base of Evidence-Based Medicine: Response.  135:245-246. 2009
• Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled β 2 -Agonists in Achieving Asthma Control.  134:1192-1199. 2008
• Eosinophil Progenitors in Airway Diseases.  134:1037-1043. 2008
• Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial).  134:794-800. 2008
• Rapid Effect of Inhaled Ciclesonide in Asthma.  134:740-745. 2008
• THE EFFECT OF ALLERGEN SELECTION ON AIRWAY RESPONSES AFTER ALLERGEN CHALLENGE USED FOR THE EVALUATION OF DRUG THERAPY IN ASTHMA.  134:6P-6P. 2008
• Asthma Management by Monitoring Sputum Neutrophil Count.  134:628-630. 2008
• Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition) (Chest (June 2008) 133 SUPPL (110S-112S)).  134:473. 2008
• Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (vol 133, pg 110S, 2008).  134:473-473. 2008
• Grades of recommendation for antithrombotic agents (vol 133, pg 123S, 2008).  134:473-473. 2008
• Methodology of antithrombotic and thrombolytic therapy guideline development (vol 133, pg 133S, 2008).  134:473-473. 2008
• New antithrombotic drugs (vol 133, pg 234S, 2008).  134:473-473. 2008
• Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition) (vol 133, pg 141S, 2008).  134:474-474. 2008
• What Is the Burden of Chronic Cough for Families?.  134:303-309. 2008
• Antiplatelet Drugs.  133:199S-233S. 2008
• Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes.  133:670S-707S. 2008
• Antithrombotic Therapy in Neonates and Children.  133:887S-968S. 2008
• Antithrombotic and Thrombolytic Therapy.  133:110S-112S. 2008
• Executive Summary.  133:71S-109S. 2008
• Grades of Recommendation for Antithrombotic Agents.  133:123S-131S. 2008
• Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment.  133:257S-298S. 2008
• Methodology for Antithrombotic and Thrombolytic Therapy Guideline Development.  133:113S-122S. 2008
• New Antithrombotic Drugs.  133:234S-256S. 2008
• Parenteral Anticoagulants.  133:141S-159S. 2008
• Pharmacology and Management of the Vitamin K Antagonists.  133:160S-198S. 2008
• Reflecting on Eight Editions of the American College of Chest Physicians Antithrombotic Guidelines.  133:1293-1295. 2008
• The Perioperative Management of Antithrombotic Therapy.  133:299S-339S. 2008
• The Primary and Secondary Prevention of Coronary Artery Disease.  133:776S-814S. 2008
• Treatment and Prevention of Heparin-Induced Thrombocytopenia.  133:340S-380S. 2008
• Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy.  133:844S-886S. 2008
• Long-Acting Bronchodilators in COPD.  133:1057-1058. 2008
• Modifying Track Layout From Straight to Circular Has a Modest Effect on the 6-min Walk Distance.  133:1155-1160. 2008
• Point: Evidence-Based Medicine Has a Sound Scientific Base.  133:1067-1071. 2008
• Rebuttal From Dr. Guyatt et al.  133:1074-1075. 2008
• Development of a Parent-Proxy Quality-of-Life Chronic Cough-Specific Questionnaire.  133:386-395. 2008
• Sputum Eosinophils and the Response of Exercise-Induced Bronchoconstriction to Corticosteroid in Asthma.  133:404-411. 2008
• So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?.  132:1108-1110. 2007
• Regulatory T Cells in Allergy and Asthma.  132:1007-1014. 2007
• Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients.  132:936-945. 2007
• Acute Exacerbations of COPD in Subjects Completing Pulmonary Rehabilitation.  132:127-134. 2007
• Contrast Echocardiography Grading Predicts Pulmonary Arteriovenous Malformations on CT.  132:18-23. 2007
• High-Frequency Oscillatory Ventilation for Adult Patients With ARDS.  131:1907-1916. 2007
• Who Is (Still) Getting HIT?.  131:1620-1622. 2007
• Effects of Nocturnal Noninvasive Mechanical Ventilation on Heart Rate Variability of Patients With Advanced COPD.  131:156-163. 2007
• Risk of Thrombosis With Lenalidomide and Its Prevention With Aspirin.  131:275-277. 2007
• Morbidity and Mortality of Patients With Invasive Group A Streptococcal Infections Admitted to the ICU.  130:1679-1686. 2006
• Effect of Rollator Use on Health-Related Quality of Life in Individuals With COPD.  130:1089-1095. 2006
• MINIMIZING COSTS FOR TREATING DEEP VEIN THROMBOSIS: THE ROLE FOR FONDAPARINUX.  130:260S-260S. 2006
• SYMPTOM CONTROL, PATIENT SATISFACTION, AND TREATMENT COMPLIANCE IN PATIENTS WITH MILD ASTHMA PRESCRIBED LOW-DOSE INHALED CORTICOSTEROIDS.  130:96S-96S. 2006
• Gene Therapy for Pulmonary Diseases.  130:879-884. 2006
• Montelukast Treatment Attenuates the Increase in Myofibroblasts Following Low-Dose Allergen Challenge.  130:741-753. 2006
• The Salmeterol Multicenter Asthma Research Trial.  130:928-928. 2006
• Think of HIT When Thrombosis Follows Heparin.  130:631-632. 2006
• Staphylococcus aureus in Community-Acquired Pneumonia.  130:623-623. 2006
• Understanding Cardiopulmonary Resuscitation Decision Making.  130:419-428. 2006
• Cytokines or Their Antagonists for the Treatment of Asthma.  130:244-250. 2006
• Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma.  129:1478-1485. 2006
• Thrombotic End Point for Assessing Argatroban Therapy for Heparin-Induced Thrombocytopenia.  129:1396-1398. 2006
• In Reply: Aerosol Delivery Devices.  129:1389-1389. 2006
• Impact of Pulmonary Rehabilitation on Psychosocial Morbidity in Patients With Severe COPD.  129:899-904. 2006
• Intensive Care and Emergency Medicine.  129:1061-1067. 2006
• Pulmonary Function and Abdominal Adiposity in the General Population.  129:853-862. 2006
• The Ontario Asthma Regional Variation Study.  129:909-917. 2006
• Treatment Strategy for Asthma.  129:221-223. 2006
• Addressing Resource Allocation Issues in Recommendations From Clinical Practice Guideline Panels.  129:182-187. 2006
• Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines.  129:174-181. 2006
• β2 Déjà Vu.  129:3-5. 2006
• CARDIO-PULMONARY MEDICAL HISTORY AND THE EFFECT ON CLINICAL OUTCOME OF COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS TREATED WITH GEMIFLOXACIN.  128:372S-372S. 2005
• Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism.  128:2203-2210. 2005
• Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization.  128:1980-1988. 2005
• Glycopyrrolate Causes Prolonged Bronchoprotection and Bronchodilatation in Patients With Asthma.  128:1974-1979. 2005
• PATIENT RISK FACTORS IN COMMUNITY-ACQUIRED PNEUMONIA INFECTIONS OUTCOME FOLLOWING TREATMENT WITH GEMIFLOXACIN.  128:372S-372S. 2005
• THE EFFECT OF DISEASE SEVERITY ON CLINICAL OUTCOME WITH ACUTE EXACERBATION OF CHRONIC BRONCHITIS PATIENTS TREATED WITH GEMIFLOXACIN.  128:371S-371S. 2005
• A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway.  127:1999-2006. 2005
• Dose Capping Enoxaparin Is Unjustified and Denies Patients With Acute Coronary Syndromes a Potentially Effective Treatment.  127:2288-2289. 2005
• Warfarin Maintenance Dosing Patterns in Clinical Practice.  127:2049-2056. 2005
• Heparin-Induced Skin Lesions and Other Unusual Sequelae of the Heparin-Induced Thrombocytopenia Syndrome.  127:1857-1861. 2005
• Lung Volume Reduction Surgery vs Medical Treatment^*.  127:1166-1166. 2005
• Asthma in Remission.  127:845-850. 2005
• New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia.  127:35S-45S. 2005
• The Pathophysiology of Heparin-Induced Thrombocytopenia.  127:9S-20S. 2005
• Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines.  127:335-371. 2005
• Malignant Pleural Mesothelioma.  126:1318-1329. 2004
• Plasma D-dimer for Outcome Assessment in Patients With CAP.  126:1015-1016. 2004
• Primary Pulmonary Sporotrichosis: A Case Report.  126:945S-945S. 2004
• Short-course Gemifloxacin Therapy is Effective Against Streptococcus pneumoniae in a Murine Model of Pneumonia.  126:847S-847S. 2004
• Antithrombotic Therapy During Percutaneous Coronary Intervention.  126:576S-599S. 2004
• Antithrombotic Therapy for Coronary Artery Disease.  126:513S-548S. 2004
• Antithrombotic Therapy in Children*.  126:645S-687S. 2004
• Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts.  126:600S-608S. 2004
• Antithrombotic and Thrombolytic Therapy: From Evidence to Application.  126:688S-696S. 2004
• Applying the Grades of Recommendation for Antithrombotic and Thrombolytic Therapy.  126:179S-187S. 2004
• Hemorrhagic Complications of Anticoagulant Treatment.  126:287S-310S. 2004
• Heparin and Low-Molecular-Weight Heparin.  126:188S-203S. 2004
• Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention.  126:311S-337S. 2004
• Methodology for Guideline Development for the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy.  126:174S-178S. 2004
• New Anticoagulant Drugs.  126:265S-286S. 2004
• Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects.  126:234S-264S. 2004
• The Pharmacology and Management of the Vitamin K Antagonists.  126:204S-233S. 2004
• The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  126:172S-173S. 2004
• Use of Antithrombotic Agents During Pregnancy.  126:627S-644S. 2004
• Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points.  126:501-508. 2004
• Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome.  125:1616-1621. 2004
• Geographic and Gender Variability in the Prevalence of Bronchial Responsiveness in Canada.  125:1657-1664. 2004
• Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia.  125:1888-1901. 2004
• Measuring Health-Related Quality of Life in Adults During an Acute Asthma Exacerbation.  125:93-97. 2004
• Advances and Contemporary Issues in Prophylaxis for Deep Vein Thrombosis.  124:347S-348S. 2003
• Advances and contemporary issues in prophylaxis for deep vein thrombosis..  124:347S-348S. 2003
• Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery.  124:379S-385S. 2003
• Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery..  124:379S-385S. 2003
• Temporal Trends in Prevention of Venous Thromboembolism Following Primary Total Hip or Knee Arthroplasty 1996–2001.  124:349S-356S. 2003
• Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry..  124:349S-356S. 2003
• A Comparison of the Original Chronic Respiratory Questionnaire With a Standardized Version.  124:1421-1429. 2003
• Relation Between Lung Function and RBC Distribution Width in a Population-Based Study*.  124:494-500. 2003
• A Meta-analysis of Nocturnal Noninvasive Positive Pressure Ventilation in Patients With Stable COPD.  124:337-343. 2003
• Dying in the ICU.  124:392-397. 2003
• Evaluation of a Practice Guideline for Noninvasive Positive-Pressure Ventilation for Acute Respiratory Failurea.  123:2062-2073. 2003
• Short-term Noninvasive Pressure Support Ventilation Prevents ICU Admittance in Patients With Acute Cardiogenic Pulmonary Edemaa.  123:2057-2061. 2003
• Airway hyperresponsiveness..  123:411S-416S. 2003
• Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur.  124:371S-371S. 2003
• Effects of Nebulized Diethylenetetraamine-NONOate in a Mouse Model of Acute Pseudomonas aeruginosa Pneumonia.  122:2127-2136. 2002
• A Randomized Controlled Trial to Evaluate the Effect of Informing Patients About Their Pretreatment Responses to Two Respiratory Questionnaires.  122:1701-1708. 2002
• Effect of Air Filtration Systems on Asthma.  122:1535-1542. 2002
• The Short-term Effect of a Rollator on Functional Exercise Capacity Among Individuals With Severe COPD.  122:56-65. 2002
• Clinically Important Improvements in Asthma-Specific Quality of Life, But No Difference in Conventional Clinical Indexes in Patients Changed From Conventional Beclomethasone Dipropionate to Approximately Half the Dose of Extrafine Beclomethasone Dipropionate.  121:1824-1832. 2002
• Safety of Pressure-Volume Curve Measurement in Acute Lung Injury and ARDS Using a Syringe Technique.  121:1595-1601. 2002
• The Design of Randomized Clinical Trials in Critically Ill Patients.  121:1290-1300. 2002
• Coronary Artery Air Embolism Complicating a CT-Guided Transthoracic Needle Biopsy of the Lung.  121:993-996. 2002
• MIASMA.  121:1003-1004. 2002
• Airway Hyperresponsiveness and Calcium Handling by Smooth Muscle.  121:621-624. 2002
• Discharge Criteria From Perioperative Physical Therapy.  121:488-494. 2002
• Evidence-Based Guidelines for Weaning and Discontinuing Ventilatory Support.  120:375S-395S. 2001
• Introduction to a Series of Systematic Reviews of Weaning From Mechanical Ventilation.  120:396S-399S. 2001
• Mechanical Ventilator Weaning Protocols Driven by Nonphysician Health-Care Professionals.  120:454S-463S. 2001
• Pharmacoeconomics in Pediatric Asthma.  120:1762-1763. 2001
• Predicting Success in Weaning From Mechanical Ventilation.  120:400S-424S. 2001
• Qualitative Studies on the Patient's Experience of Weaning From Mechanical Ventilation.  120:469S-473S. 2001
• Treatment of Warfarin-Associated Coagulopathy.  120:1972-1976. 2001
• Trials Comparing Alternative Weaning Modes and Discontinuation Assessments.  120:425S-437S. 2001
• Trials Comparing Early vs Late Extubation Following Cardiovascular Surgery.  120:445S-453S. 2001
• Trials of Corticosteroids to Prevent Postextubation Airway Complications.  120:464S-468S. 2001
• Trials of Miscellaneous Interventions to Wean From Mechanical Ventilation.  120:438S-444. 2001
• Exercise Not Asthma.  120:1434-1435. 2001
• Differential Cell Counts in Sputum in Respiratory Epidemiology.  120:1107-1113. 2001
• Home Oxygen Requalification.  120:318-319. 2001
• Do Blood Transfusions Improve Outcomes Related to Mechanical Ventilation?.  119:1850-1857. 2001
• Deleterious Effects of Inhaled β-Agonists.  119:1297-1299. 2001
• Sleep in critically ill patients requiring mechanical ventilation (vol. 117, pg 809, 2000).  119:993-993. 2001
• Marked Tachypnea in Siblings With Chronic Beryllium Disease due to Copper-Beryllium Alloy.  119:647-650. 2001
• Nutritional Intervention in COPD.  119:353-363. 2001
• A Qualitative Systematic Overview of the Measurement Properties of Functional Walk Tests Used in the Cardiorespiratory Domain.  119:256-270. 2001
• Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention.  119:321S-336S. 2001
• Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves.  119:220S-227S. 2001
• Antithrombotic therapy in patients undergoing percutaneous coronary intervention.  119:321S-336S. 2001
• Grades of Recommendation for Antithrombotic Agents.  119:3S-7S. 2001
• Hemorrhagic Complications of Anticoagulant Treatment.  119:108S-121S. 2001
• Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety.  119:64S-94S. 2001
• Left Ventricular Wall Stress During Leg-Press Exercise Performed With a Brief Valsalva Maneuver.  119:150-154. 2001
• Managing Oral Anticoagulant Therapy.  119:22S-38S. 2001
• Managing oral anticoagulant therapy..  119:22S-38S. 2001
• New Anticoagulant Drugs.  119:95S-107S. 2001
• New anticoagulant drugs.  119:95S-107S. 2001
• Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range.  119:8S-21S. 2001
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range..  119:8S-21S. 2001
• Platelet-Active Drugs.  119:39S-63S. 2001
• Platelet-active drugs : the relationships among dose, effectiveness, and side effects..  119:39S-63S. 2001
• The Sixth (2000) ACCP Guidelines for Antithrombotic Therapy for Prevention and Treatment of Thrombosis.  119:1S-2S. 2001
• The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians..  119:1S-2S. 2001
• Use of Antithrombotic Agents During Pregnancy.  119:122S-131S. 2001
• Use of antithrombotic agents during pregnancy..  119:122S-131S. 2001
• Appropriateness of Domiciliary Oxygen Delivery.  118:1303-1308. 2000
• Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure.  118:914-922. 2000
• Dissecting Aortic Aneurysm.  118:880-880. 2000
• Pulmonary Function Is a Long-term Predictor of Mortality in the General Population.  118:656-664. 2000
• Acute Airway Obstruction Secondary to Bilateral Broncholithiasis.  117:1205-1207. 2000
• Endotracheal Aspiration in the Diagnosis of Ventilator-Associated Pneumonia.  117:195S-197S. 2000
• Long-term Effects of Outpatient Rehabilitation of COPD.  117:976-983. 2000
• Nutritional Support for Individuals With COPD.  117:672-678. 2000
• Sleep in Critically Ill Patients Requiring Mechanical Ventilation.  117:809-818. 2000
• Exogenous lipid pneumonia related to smoking "weed oil" in association with pulmonary alveolar proteinosis post cadaveric renal transplantation.  116. 1999
• Health-Related Quality of Life in Moderate Asthma.  116:1297-1303. 1999
• Physician Preferences for Perioperative Anticoagulation in Patients With a Mechanical Heart Valve Who Are Undergoing Elective Noncardiac Surgery.  116:1240-1246. 1999
• Trends in the Epidemiology of COPD in Canada, 1980 to 1995.  116:306-313. 1999
• Heparin and low-molecular-weight heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety (vol 114, pg 495S, 1998).  115:1760-1760. 1999
• A Randomized Controlled Trial on the Effect of Inhaled Corticosteroids on Airways Inflammation in Adult Cigarette Smokers.  115:1271-1277. 1999
• Validation of a Standardized Version of the Asthma Quality of Life Questionnaire.  115:1265-1270. 1999
• The Clinical Utility of Invasive Diagnostic Techniques in the Setting of Ventilator-Associated Pneumonia.  115:1076-1084. 1999
• Percutaneous tracheostomy: is it really better?.  114:1771-1772. 1998
• Reversal of the Anticoagulant Effects of Warfarin by Vitamin K1.  114:1505-1508. 1998
• Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty.  114:728S-741S. 1998
• Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves.  114:602S-610S. 1998
• Antithrombotic therapy in patients undergoing coronary angioplasty.  114:728S-741S. 1998
• Grades of Recommendation for Antithrombotic Agents.  114:441S-444S. 1998
• Hemorrhagic Complications of Anticoagulant Treatment.  114:511S-523S. 1998
• Heparin and Low-Molecular-Weight Heparin.  114:489S-510S. 1998
• Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety..  114:489S-510S. 1998
• New Antithrombotic Agents.  114:715S-727S. 1998
• New antithrombotic agents.  114:715S-727S. 1998
• Oral Anticoagulants.  114:445S-469S. 1998
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range..  114:445S-469S. 1998
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects..  114:470S-488S. 1998
• Use of Antithrombotic Agents During Pregnancy.  114:524S-530S. 1998
• Use of antithrombotic agents during pregnancy..  114:524S-530S. 1998
• Intratracheal Pulmonary Ventilation at Low Airway Pressures in a Ventilator-Induced Model of Acute Respiratory Failure Improves Lung Function and Survival.  114:1147-1157. 1998
• The Effect of Positive Pressure Airway Support on Mortality and the Need for Intubation in Cardiogenic Pulmonary Edema.  114:1185-1192. 1998
• Evidence for the Needs of Out-of-Hospital Thrombosis Prophylaxis.  114:113S-114S. 1998
• Managing Cough as a Defense Mechanism and as a Symptom.  114:133S-181S. 1998
• The Incidence of Symptomatic Venous Thromboembolism After Enoxaparin Prophylaxis in Lower Extremity Arthroplasty.  114:115S-118S. 1998
• The Timing of Tracheotomy.  114:605-609. 1998
• Is It ‘Worthwhile' To Continue Treating Patients With a Prolonged Stay (>14 Days) in the ICU?.  114:192-198. 1998
• Is There Really A Controversy Surrounding the Effectiveness of Respiratory Rehabilitation in COPD?.  114:1-4. 1998
• The Influence of 6 Months of Oral Anabolic Steroids on Body Mass and Respiratory Muscles in Undernourished COPD Patients.  114:19-28. 1998
• Nosocomial Pneumonia Guidelines.  113:188S-193S. 1998
• Benefit of Heparin in Central Venous and Pulmonary Artery Catheters.  113:165-171. 1998
• Intratracheal Pulmonary Ventilation and Continuous Positive Airway Pressure in a Sheep Model of Severe Acute Respiratory Failure.  112:1060-1067. 1997
• A New Index of Prognostic Severity for Chronic Asthma.  112:582-590. 1997
• Respiratory Failure Following Vinorelbine Tartrate Infusion in a Patient With Non-small Cell Lung Cancer.  112:846-848. 1997
• Economic Analysis of Respiratory Rehabilitation.  112:370-379. 1997
• Adenovirus-mediated gene transfer of the proteoglycan biglycan induces fibroblastic responses in the lung..  111:137S. 1997
• In vivo adenovirus-mediated expression of human pre-elafin, a potent neutrophil elastase inhibitor..  111:128S-129S. 1997
• Transient Gene Transfer and Expression in the Lung.  111:89S-94S. 1997
• The Components of a Respiratory Rehabilitation Program.  111:1077-1088. 1997
• Introduction.  111:1S-1S. 1997
• Leukotrienes in the Pathogenesis of Asthma.  111:27S-34S. 1997
• Mycobacterium avium Complex Infection in an Immunocompetent Young Adult Related to Hot Tub Exposure.  111:242-245. 1997
• Symptom Intensity and Subjective Limitation to Exercise in Patients With Cardiorespiratory Disorders.  110:1255-1263. 1996
• Asthma quality of life survey.  110. 1996
• Misunderstanding and misuse: Canadian asthmatics' patterns of use and knowledge of Inhaled Steroids (IS).  110. 1996
• Quality of Life (QOL) of Canadian asthma sufferers.  110. 1996
• Risk factors for breakthrough PCP in HIV-infected patients receiving aerosol pentamidine.  110. 1996
• An Effectiveness Community-Based Clinical Trial of Respirgard II and Fisoneb Nebulizers for Pneumocystis carinii Prophylaxis With Aerosol Pentamidine in HIV-Infected Individuals.  110:141-146. 1996
• Long-acting β-Agonists, Tachyphylaxis, and Corticosteroids.  109:862-864. 1996
• Pulmonary Embolism With Duplicated Inferior Vena Cava.  109:1111-1113. 1996
• Metered-Dose Inhaler Salbutamol-Induced Tracheal Epithelial Lesions in Intubated Rabbits.  108:1668-1672. 1995
• Antithrombotic Therapy for Cerebrovascular Disorders.  108:444S-456S. 1995
• Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty.  108:486S-501S. 1995
• Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves.  108:371S-379S. 1995
• Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts.  108:424S-430S. 1995
• Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects..  108:247S-257S. 1995
• Clinical Recommendations Using Levels of Evidence for Antithrombotic Agents.  108:227S-230S. 1995
• Hemorrhagic Complications of Anticoagulant Treatment.  108:276S-290S. 1995
• Hemorrhagic complications of anticoagulant treatment..  108:276S-290S. 1995
• Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism..  108:291S-301S. 1995
• Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety.  108:258S-275S. 1995
• Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety..  108:258S-275S. 1995
• New Antithrombotics.  108:471S-485S. 1995
• Oral Anticoagulants.  108:231S-246S. 1995
• Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range..  108:231S-246S. 1995
• Prevention of Venous Thromboembolism.  108:312S-334S. 1995
• Community-Acquired Pneumonia.  108:35S-42S. 1995
• Regular β-Adrenergic Agonists.  108:589-590. 1995
• Regular β-Adrenergic Agonists-To the Editor.  108:590-590. 1995
• Interobserver Variation in the Computed Tomographic Evaluation of Mediastinal Lymph Node Size in Patients With Potentially Resectable Lung Cancer.  107:116-119. 1995
• Occupational Exposure and Pulmonary Function in Health Care Workers in an Aerosol Pentamidine Clinic.  106:980-981. 1994
• Reduced Dose Bolus Alteplase vs Conventional Alteplase Infusion for Pulmonary Embolism Thrombolysis.  106:718-724. 1994
• Regular Beta-Adrenergic Agonists.  106:552-559. 1994
• Dose-effect Relationship of the β-Agonists Fenoterol and Salbutamol in Patients With Asthma.  105:1738-1742. 1994
• Mortality Risk and Patterns of Practice in 2,070 Patients With Acute Myocardial Infarction, 1987-92.  105:1687-1692. 1994
• Oral Anticoagulants-To the Editor.  105:1903-1903. 1994
• Effect of Magnitude of Airway Responsiveness and Therapy With Inhaled Corticosteroid on Histamine Tachyphylaxis in Asthma.  105:1434-1438. 1994
• Selective Decontamination of the Digestive Tract.  105:1221-1229. 1994
• Prevention and Regression of Coronary Atherosclerosis.  105:718-726. 1994
• Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents.  105:647-647. 1994
• Efficiency of Bronchodilator Aerosol Delivery to the Lungs From the Metered Dose Inhaler in Mechanically Ventilated Patients.  105:214-218. 1994
• Oral Anticoagulant Therapy Recommendations.  105:328-328. 1994
• D-Dimer in Patients With Clinically Suspected Pulmonary Embolism.  104:1679-1684. 1993
• β-Agonists and Bronchial Asthma.  104:652-653. 1993
• A Placebo-controlled Dose-finding Study With Bambuterol in Elderly Patients With Asthma.  103:771-776. 1993
• Dosing Efficiency and Particle-size Characteristics of Pressurized Metered-dose Inhaler Aerosols in Narrow Catheters.  103:920-924. 1993
• Exposure of Health-Care Workers to Aerosolized Pentamidine.  103:982-983. 1993
• Treatment of Community-acquired Pneumonia.  103:697-701. 1993
• Concurrent Catamenial Hemothorax and Hemopneumothorax.  103:646-648. 1993
• Management of Metastatic Non-Small-Cell Lung Cancer and a Consideration of Cost.  103:68S-71S. 1993
• Management of metastatic non-small-cell lung cancer and a consideration of cost.  103:68S-71. 1993
• Increased Inhaled Bronchodilator vs Increased Inhaled Corticosteroid in the Control of Moderate Asthma.  102:1709-1715. 1992
• Skeletal Muscle Metabolism in the Chronic Fatigue Syndrome.  102:1716-1722. 1992
• Antithrombotic Agents in Coronary Artery Disease.  102:456S-481S. 1992
• Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves.  102:445S-455S. 1992
• Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts Following Percutaneous Transluminal Coronary Angioplasty.  102:508S-515S. 1992
• Antithrombotic therapy. Introduction..  102:303S-304S. 1992
• Aspirin and Other Platelet-Active Drugs.  102:327S-336S. 1992
• Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects..  102:327S-336S. 1992
• Cardiac Output Determination during Progressive Exercise in Cystic Fibrosis.  102:1118-1123. 1992
• Hemorrhagic Complications of Anticoagulant Treatment.  102:352S-363S. 1992
• Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism.  102:364S-373S. 1992
• Hemorrhagic complications of anticoagulant treatment..  102:352S-363S. 1992
• Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism..  102:364S-373S. 1992
• Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety.  102:337S-351S. 1992
• Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety..  102:337S-351S. 1992
• Oral Anticoagulants.  102:312S-326S. 1992
• Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.  102:312S-326. 1992
• Prevention of Venous Thromboembolism.  102:391S-407S. 1992
• RULES OF EVIDENCE AND CLINICAL RECOMMENDATIONS ON THE USE OF ANTITHROMBOTIC AGENTS.  102:S305-S311. 1992
• Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents.  102:305S-311S. 1992
• Use of Antithrombotic Agents During Pregnancy.  102:385S-390S. 1992
• Use of antithrombotic agents during pregnancy..  102:385S-390S. 1992
• Ciliary Function, Cell Viability, and in Vitro Effect of Ribavirin on Nasal Epithelial Cells in Acute Rhinorrhea.  102:284-287. 1992
• The Clinical Utility of Postinfarction Risk Prediction.  101:534-540. 1992
• Gastric Colonization by Gram-Negative Bacilli and Nosocomial Pneumonia in the Intensive Care Unit Patient.  101:187-193. 1992
• Plasma cell pneumonia induced by Legionella pneumophila..  100:1170-1172. 1991
• Nosocomial Pneumonia and the Role of Gastric pH.  100:7-13. 1991
• Randomized Trials to Assess the Long-term Effects of Therapies on Angiographic End Points.  99:1243-1247. 1991
• Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism..  99:128S-128S. 1991
• Allergistis non Carborundum.  99:522-522. 1991
• A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism.  98:1473-1479. 1990
• Clinical Dysautonomia in Patients with Bronchial Asthma.  98:1408-1413. 1990
• Recidivism Revisited.  98:790-791. 1990
• A NEW SHORT INFUSION DOSAGE REGIMEN OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE.  97:S168-S171. 1990
• A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease.  97:168S-171S. 1990
• Tissue Plasminogen Activator (rt-PA) vs Heparin in Deep Vein Thrombosis.  97:172S-175S. 1990
• Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial..  97:172S-175S. 1990
• Accuracy of Asthma Mortality in France.  97:508-509. 1990
• Clinical Validity of a Normal Perfusion Lung Scan in Patients with Suspected Pulmonary Embolism.  97:23-26. 1990
• ADJUVANT THERAPY FOR NON-SMALL CELL LUNG-CANCER.  96:S87-S91. 1989
• Adjuvant therapy for non-small cell lung cancer..  96:87S-91S. 1989
• The Cardiopulmonary and Renal Hemodynamic Effects of Norepinephrine in Canine Pulmonary Embolism.  95:1333-1337. 1989
• Pulmonary Infiltration with Blood Eosinophilia after Scorpion Sting.  95:691-692. 1989
• ASPIRIN AND OTHER PLATELET ACTIVE-DRUGS - RELATIONSHIP AMONG DOSE, EFFECTIVENESS, AND SIDE-EFFECTS.  95:S12-S18. 1989
• Antithrombotic Agents in Coronary Artery Disease.  95:52S-72S. 1989
• Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects.  95:12S-18. 1989
• HEMORRHAGIC COMPLICATIONS OF THROMBOLYTIC THERAPY IN THE TREATMENT OF MYOCARDIAL-INFARCTION AND VENOUS THROMBOEMBOLISM.  95:S88-S97. 1989
• Hemorrhagic Complications of Long-term Anticoagulant Therapy.  95:26S-36S. 1989
• Hemorrhagic Complications of Thrombolytic Therapy in the Treatment of Myocardial Infarction and Venous Thromboembolism.  95:88S-97S. 1989
• Hemorrhagic complications of long-term anticoagulant therapy..  95:26S-36S. 1989
• Optimal Therapeutic Range for Oral Anticoagulants.  95:5S-11S. 1989
• Optimal therapeutic range for oral anticoagulants [published erratum appears in Chest 1989 Oct;96(4):962].  95:5S-11. 1989
• Optimal therapeutic range for oral anticoagulants..  95:5S-11S. 1989
• Use of Anticoagulants during Pregnancy.  95:156S-160S. 1989
• Use of anticoagulants during pregnancy..  95:156S-160S. 1989
• International Trends in Asthma Mortality: 1970 to 1985.  94:914-918. 1988
• Comparison of the Effects of Nebulized Terbutaline with Intravenous Enprofylline in Patients with Acute Asthma.  93:510-514. 1988
• The Diagnosis and Management of Supraventricular Tachycardia by Transesophageal Cardiac Stimulation and Recording.  93:339-344. 1988
• Cardiovascular Effects of Smoking in Patients with Ischemic Heart Disease.  93:14-19. 1988
• THE USE OF BETA-ADRENERGIC BLOCKING-AGENTS, IV NITRATES AND CALCIUM-CHANNEL BLOCKING-AGENTS FOLLOWING ACUTE MYOCARDIAL-INFARCTION.  93:S25-S28. 1988
• The Use of Beta-adrenergic Blocking Agents, IV Nitrates and Calcium Channel Blocking Agents following Acute Myocardial Infarction.  93:25S-28S. 1988
• Measurement of Cardiac Output by CO2 Rebreathing in Unsteady State Exercise.  92:777-782. 1987
• A Controlled Trial of Ambroxol in Chronic Bronchitis.  92:618-620. 1987
• Rigorous Evaluation.  92:580-581. 1987
• Airway Inflammation and Airway Hyperresponsiveness.  90:575-577. 1986
• A Meta-analysis of the Studies of Dihydroergotamine plus Heparin in the Prophylaxis of Deep Vein Thrombosis.  89:396S-400S. 1986
• Introduction.  89:369S-369S. 1986
• Prophylaxis of Venous Thromboembolism.  89:374S-383S. 1986
• Prophylaxis of venous thromboembolism. An overview..  89:374S-383S. 1986
• TREATMENT OF VENOUS THROMBOEMBOLISM.  89:S426-S433. 1986
• Treatment of Venous Thromboembolism.  89:426S-433S. 1986
• Venous Thromboembolism.  89:370S-373S. 1986
• Venous thromboembolism. Scope of the problem.  89:370S-373. 1986
• "Therapeutic range" for oral anticoagulant therapy..  89:11S-15S. 1986
• Antithrombotic Agents in Coronary Artery Disease.  89:54S-67S. 1986
• Dose Antiplatelet Agents; The Relationship Among Side Effects, and Antithrombotic Effectiveness.  89:4S-10S. 1986
• Hemorrhagic Complications of Long-term Anticoagulant Therapy.  89:16S-25S. 1986
• Hemorrhagic complications of long-term anticoagulant therapy..  89:16S-25S. 1986
• “Therapeutic Range” for Oral Anticoagulant Therapy.  89:11S-15S. 1986
• Diagnostic Value of Ventilation-Perfusion Lung Scanning in Patients with Suspected Pulmonary Embolism.  88:819-828. 1985
• Hemodynamic and Myocardial Metabolic Consequences of PEEP.  88:496-502. 1985
• Isoxsuprine and Pulmonary Edema.  88:643-644. 1985
• Are Active and Passive Smoking Harmful?.  88:445-451. 1985
• The Objective Measurement of Breathlessness.  88:84S-90S. 1985
• Inhalation Challenge Tests and Airway Responsiveness in Man.  87:202S-206S. 1985
• Advances in the Use of Inhalation Provocation Tests in Clinical Evaluation.  87:32S-35S. 1985
• Inhalation challenge tests and airway responsiveness in man.  87:2025-2055. 1985
• Sotalol Infusion in the Treatment of Supraventricular Tachyarrhythmias.  87:113-118. 1985
• Noninvasive Measurement of Mixed Venous Pco 2.  85:449-450. 1984
• The preferential deposition of inhaled isoproterenol and propranolol in asthmatic patients.  80:904-907. 1981
• The preferential deposition of inhaled isoproterenol and propranolol in asthmatic patients..  80:904-907. 1981
• THE DYSKINETIC CILIA SYNDROME - ABNORMAL CILIARY MOTILITY IN ASSOCIATION WITH ABNORMAL CILIARY ULTRASTRUCTURE.  80:860-864. 1981
• What's in Exercise?.  78:678-679. 1980
• The Dyskinetic Cilia Syndrome.  78:580-582. 1980
• Chlorpromazine and Dopamine in Shock.  74:319-319. 1978
• Aerosol Therapy with Sch 1000.  73:501-506. 1978
• Measurements of Cardiac Output in Seriously Ill Patients Using a CO2 Rebreathing Method.  73:167-172. 1978
• Use of Exercise in Testing Respiratory Control Mechanisms.  70:169-173. 1976
• Restoration of Regional Wall Motion by Nitroglycerin Therapy in Patients with Left Ventricular Asynergy.  66:545-548. 1974

has subject area

• 1103 Clinical Sciences (FoR)
• Respiratory System (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0012-3692
• 1931-3543

Electronic International Standard Serial Number (EISSN)

• 1931-3543